GDF15: a potential therapeutic target for type 1 diabetes

Area of Science:

• Endocrinology
• Immunology
• Metabolic Research

Background:

• Type 1 diabetes (T1D) management relies on insulin therapy due to pancreatic beta cell loss.
• Growth Differentiation Factor 15 (GDF15) is a protein with diverse biological effects, including metabolic, feeding, and immunomodulatory functions.

Purpose of the Study:

• To explore the potential of GDF15 as a preventative therapy for type 1 diabetes.
• To examine GDF15's role in preventing insulitis and protecting pancreatic beta cells from inflammatory stress.

Main Methods:

• Review of current literature on GDF15's known actions and effects.
• Analysis of preclinical study findings regarding GDF15 efficacy and challenges.
• Discussion of potential therapeutic strategies, including systems pharmacology and chronotherapy.

Main Results:

• GDF15 demonstrates promise in preclinical models for preventing insulitis and protecting beta cells.
• Preclinical studies reported limited efficacy, potentially due to measuring total GDF15 instead of its active form.
• Challenges include GDF15-induced anorexia, nausea, and a short half-life.

Conclusions:

• GDF15 presents a potential therapeutic avenue for type 1 diabetes prevention.
• Further research is critical to optimize GDF15 delivery and overcome its limitations.
• A systems pharmacology approach combined with chronotherapy may offer solutions for GDF15-based therapies.